Japan’s Sawai Benefits In Domestic Market From Rivals’ Supply Misery

Sawai Pharmaceutical Co., Ltd. benefitted from domestic supply stoppages of products from other Japanese generics manufacturers in its financial first quarter ended 30 June 2021, although one analyst cautioned that the firm “lacks sufficient excess production capacity to handle the sharp expansion in demand.”

Domestic turnover increased by just under a quarter to ¥43.5bn ($396m), while the Japanese business’ core operating profit leapt by 34.9% to ¥9